LabCorp Licenses Celera's Breast Cancer Receptor Patents | GenomeWeb
NEW YORK (GenomeWeb News) — Celera said today it has licensed its estrogen/progesterone receptor patents to LabCorp, which will use the IP to commercialize two cancer tests.
 
The reference lab giant will use one test to predict risk of metastasis in early-stage breast cancer, while the other will assess hormone-receptor status to help plan endocrine therapy.
 
Under the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of lab services and tests that use the IP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.